List of Excipients in Branded Drug CIPRO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	CIPRO	ciprofloxacin hydrochloride and hydrocortisone	0065-8531	ACETIC ACID
Alcon Laboratories Inc	CIPRO	ciprofloxacin hydrochloride and hydrocortisone	0065-8531	BENZYL ALCOHOL
Alcon Laboratories Inc	CIPRO	ciprofloxacin hydrochloride and hydrocortisone	0065-8531	HYDROCHLORIC ACID

Generic Drugs Containing CIPRO

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	ciprofloxacin	0143-9927	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	ciprofloxacin	0143-9927	CORN OIL
Hikma Pharmaceuticals USA Inc	ciprofloxacin	0143-9927	HYPROMELLOSES

What are the Most Frequently-Used Excipients in CIPRO?

# Of NDCs	Excipient

Cipro Excipient Strategy and Commercial Opportunities for Ciprofloxacin

Last updated: August 27, 2026

Cipro, Bayer’s brand of ciprofloxacin, is a mature fluoroquinolone with extensive generic competition and limited core patent protection. Commercial opportunity has shifted from the active pharmaceutical ingredient to differentiated formulations, pediatric acceptability, ophthalmic tolerability, preservative reduction, reconstitution stability, and reliable low-cost manufacturing.

The strongest excipient opportunities are in oral suspension, taste-masked pediatric products, ophthalmic delivery, preservative-free presentations, and platform technologies that improve stability without changing ciprofloxacin exposure.

What is Cipro and which dosage forms use ciprofloxacin?

Cipro contains ciprofloxacin, usually as ciprofloxacin hydrochloride monohydrate in oral products. FDA-approved Cipro presentations have included immediate-release tablets, oral suspension, and intravenous infusion. Separate ciprofloxacin products include ophthalmic solutions, ophthalmic ointments, otic formulations, and extended-release tablets.

Dosage form	Typical strengths or concentration	Primary excipient priorities	Commercial position
Immediate-release tablets	250 mg, 500 mg, 750 mg	Compressibility, film coating, dissolution, moisture control	Highly commoditized
Oral suspension	250 mg/5 mL and 500 mg/5 mL equivalent presentations	Taste masking, sedimentation control, reconstitution stability, syringeability	Strongest formulation opportunity
Intravenous solution	Commonly 2 mg/mL	pH, precipitation control, container compatibility, particulate control	Institutional and tender-driven
Ophthalmic solution	Commonly 0.3%	Ocular comfort, preservative exposure, sterility, drop consistency	Differentiation possible
Extended-release tablet	Product-specific	Release matrix, food effect, dose dumping prevention	Technically differentiated but genericized
Otic products	Product-specific	Preservative strategy, viscosity, local tolerability	Niche opportunity

Cipro’s product labels identify excipients such as microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, hypromellose, polyethylene glycol, titanium dioxide, mannitol, povidone, polysorbate 20, sodium acetate, lactic acid, hydrochloric acid, sodium chloride, and edetate disodium, depending on the dosage form.[1]

What excipient strategies are most valuable for Cipro?

The most commercially relevant strategy is to improve usability while preserving ciprofloxacin’s established bioavailability and regulatory profile.

Taste masking for ciprofloxacin oral suspension

Ciprofloxacin has a strong bitter taste. This creates a material barrier for pediatric use, long treatment courses, and patients with swallowing difficulty.

Useful approaches include:

• Ion-exchange resin complexes
• Polymer coatings
• Lipid-based taste-masking systems
• Multiparticulate granules
• pH-controlled flavor systems
• Sweetener and flavor combinations that remain stable after reconstitution
• Encapsulation that releases ciprofloxacin after gastric transit

Ion-exchange resins can reduce immediate contact between ciprofloxacin and taste receptors. The main development risk is incomplete drug release or altered absorption. Any resin system must demonstrate rapid release under gastrointestinal conditions and avoid binding interactions with minerals, antacids, or enteral nutrition.

A commercial product that combines strong taste masking with a compact reconstitution volume could compete more effectively than another conventional suspension.

Suspension stability and redispersibility

Ciprofloxacin suspensions require control of sedimentation, caking, viscosity, and dose uniformity. Candidate excipient systems include:

• Microcrystalline cellulose and carboxymethylcellulose combinations
• Xanthan gum or other low-use-level suspending agents
• Wetting agents such as polysorbates
• Structured vehicles that maintain uniformity after storage
• Preservative systems compatible with the selected container
• Single-dose sachets or ready-to-use unit-dose cups

The target should be easy redispersion after limited shaking. Excessive viscosity can impair administration through oral syringes and reduce patient adherence. A commercially viable formulation must balance physical stability with pourability and syringeability.

Excipient selection for tablets

Immediate-release Cipro tablets are mature products. A conventional excipient substitution is unlikely to support meaningful pricing unless it solves a measurable manufacturing or stability problem.

Potential areas include:

• Direct compression systems that reduce granulation steps
• Low-moisture formulations for improved stability
• Superdisintegrants that maintain dissolution across manufacturing sites
• Film coatings that reduce bitterness without delaying release
• High-speed tableting platforms for hospital and tender volumes
• Reduced-pigment or titanium-dioxide-free coating systems

Ciprofloxacin has clinically important interaction risks with polyvalent cations. Formulation developers should avoid excipient systems that increase calcium, magnesium, aluminum, iron, or zinc exposure. This issue applies to both excipients and co-packaged products. The label warns that ciprofloxacin absorption can be reduced by antacids and mineral-containing products.[1]

What formulations are protected by Cipro-related intellectual property?

The original ciprofloxacin compound estate is expired in the United States and other major markets. Cipro’s commercial protection historically depended on Bayer’s compound patent, regulatory exclusivity, formulation patents, and litigation settlements. Generic ciprofloxacin products have been marketed for many years.

IP category	Current commercial relevance
Ciprofloxacin compound patent	Expired
Immediate-release tablet patents	Expired or commercially weak
Oral suspension technology	Potentially protectable through formulation claims
Extended-release matrices	Potentially protectable, but subject to prior-art and obviousness risk
Ophthalmic delivery systems	Narrow formulation and device claims may remain relevant
Taste-masking systems	Potentially valuable if linked to release, stability, or sensory data
Manufacturing processes	Can create practical barriers even without strong composition patents
Packaging and reconstitution systems	Usually narrow, but useful for product differentiation

A new excipient system may receive patent protection if it provides a non-obvious combination of taste masking, dissolution, stability, dose uniformity, or reduced preservative exposure. A generic “ciprofloxacin plus standard suspending agent” claim would face substantial prior-art risk.

What is the Orange Book status of Cipro?

Cipro was approved by the FDA in the 1980s and has long been subject to generic competition. The FDA Orange Book identifies approved drug products, therapeutic equivalence information, patents, and exclusivity data where applicable.[2]

For a current US diligence review, Cipro must be evaluated by specific NDA, dosage form, and strength. The relevant questions are:

1. Whether the branded NDA remains listed as active.
2. Whether any patent listings remain in the applicable Orange Book edition.
3. Whether the proposed product would use an ANDA, 505(b)(2) application, or another pathway.
4. Whether the formulation differs sufficiently to require new clinical or bioavailability evidence.
5. Whether any listed patent could trigger a Paragraph IV certification.

For a conventional immediate-release ciprofloxacin tablet, the practical barrier is generally regulatory execution and cost rather than the original compound patent. A differentiated suspension, ophthalmic product, or extended-release formulation may require more complex bioequivalence and CMC work.

When did Cipro lose exclusivity and when can generics launch?

Ciprofloxacin’s core US patent protection ended in the early 2000s, with generic entry following the expiration and settlement history surrounding Bayer’s patent estate. Generic ciprofloxacin tablets, suspension, and injectable products are now widely available.

The current commercial timeline is therefore not driven by Cipro’s original exclusivity. It is driven by:

• Approval timing for a new generic or 505(b)(2) product
• Paragraph IV litigation, if a relevant listed patent exists
• ANDA suitability of the dosage form
• Manufacturing scale-up
• State substitution rules
• Hospital formulary access
• Government tender cycles
• API and finished-dose supply reliability

A standard generic tablet can launch rapidly after approval if no blocking patent remains. A novel formulation may need a separate patent and regulatory strategy, but it will face competition from other ciprofloxacin products and from alternative antibiotics.

Are there Paragraph IV challenges involving Cipro?

Historical Paragraph IV activity involved generic manufacturers challenging Bayer-related ciprofloxacin patents, particularly around Cipro and extended-release products. Those disputes contributed to generic entry and settlement arrangements in the US.

For a new entrant, a Paragraph IV strategy would be relevant only if:

• The reference product has a currently listed patent.
• The proposed formulation falls within the patent claims.
• The applicant believes the patent is invalid, unenforceable, or not infringed.
• The expected market value justifies litigation.

For legacy immediate-release Cipro products, Paragraph IV risk is usually less important than formulation-specific patents filed by later generic or specialty pharmaceutical companies. New applicants should screen patents covering taste-masking agents, release-controlling polymers, multiparticulates, preservative systems, and ophthalmic delivery.

What patent litigation and settlement issues affect Cipro?

The historical Cipro litigation centered on Bayer’s ciprofloxacin patent and generic challenges. The disputes were commercially significant because ciprofloxacin had substantial use in respiratory, urinary, gastrointestinal, bone, skin, and post-exposure settings.

Current diligence should separate three categories:

Core product litigation

This concerns the original ciprofloxacin molecule and conventional products. The core protection is no longer the principal barrier to entry.

Follow-on formulation litigation

This can involve extended release, improved suspension systems, taste masking, ophthalmic compositions, or specific salt and particle forms. These patents can affect a particular ANDA even when the compound itself is unprotected.

Commercial settlement agreements

Historical settlements may contain launch dates, authorized-generic provisions, supply terms, or restrictions tied to specific dosage forms. Settlement terms must be reviewed product by product because an agreement covering tablets may not govern suspension, ophthalmic, or injectable products.

How strong is the Cipro patent estate?

The original Cipro estate is weak as a barrier to standard generic entry. A new formulation estate can be stronger if it has:

• Narrow but technically defensible composition claims
• Comparative taste or stability data
• Demonstrated bioequivalence
• Reduced preservative exposure
• A distinctive multiparticulate or reconstitution architecture
• Manufacturing know-how that is difficult to reverse engineer
• Claims covering both the formulation and its method of use

Patent strength is likely to be highest for a formulation that solves a clinically relevant problem and has measurable product performance. Taste masking alone may be vulnerable if the claims rely on routine excipient selection. A platform combining taste masking, rapid release, high dose uniformity, and long in-use stability has a stronger commercial case.

What FDA regulatory pathway applies to differentiated Cipro products?

A conventional ciprofloxacin tablet or suspension can generally pursue an ANDA if it matches the reference product’s dosage form, strength, route, conditions of use, and bioequivalence requirements.[3]

A 505(b)(2) application may be more appropriate for:

• A new delivery system
• A materially different formulation
• A new route or dosage form
• A product with a new clinical use
• A formulation requiring reliance on existing ciprofloxacin safety data but supported by additional studies

Ophthalmic and otic products must meet sterile manufacturing, container-closure, particulate, preservative, and microbiological quality requirements. A preservative-free multidose product may require a specialized container or delivery device and a stronger microbial protection package.

No biosimilar pathway applies because ciprofloxacin is a chemically synthesized small molecule, not a biologic. Competitive products are generics, authorized generics, 505(b)(2) products, and branded specialty formulations.

Which companies are challenging or competing with Cipro?

The ciprofloxacin market includes:

• Bayer, associated with the Cipro brand
• Large generic manufacturers such as Teva, Sandoz, Viatris, Hikma, and Dr. Reddy’s, subject to product-specific approvals
• Hospital-focused injectable suppliers
• Ophthalmic specialists
• Regional manufacturers in India, China, Latin America, and other regulated and semi-regulated markets
• Contract development and manufacturing organizations supplying ciprofloxacin formulations

Competition is fragmented. Finished-dose reliability, API sourcing, regulatory inspection history, and tender pricing often matter more than brand recognition.

What commercial opportunities exist for Cipro excipients?

Pediatric oral products

The most attractive opportunity is a palatable oral suspension or granule system with:

• Strong bitterness reduction
• Stable reconstitution
• Accurate oral-syringe dosing
• Low sedimentation
• Acceptable storage conditions
• Reduced shaking requirements
• Flavor stability over the labeled in-use period

Pediatric use is clinically constrained by fluoroquinolone safety considerations, but ciprofloxacin remains approved for selected pediatric indications, including specific complicated infections.[1] The addressable market is therefore narrower than for routine pediatric antibiotics.

Ophthalmic and otic products

Preservative-reduced or preservative-free ciprofloxacin products could compete where ocular surface tolerability is important. Excipient opportunities include alternative antimicrobial protection, low-irritancy buffers, optimized tonicity, and drop-size control.

Hospital and injectable products

For intravenous ciprofloxacin, commercial value comes from robust container compatibility, low particulate risk, long shelf life, and flexible ready-to-use presentations. Bag materials, overwraps, and administration devices can be as important as the solution excipients.

Emerging-market formulations

Lower-cost dry suspensions, sachets, dispersible tablets, and heat-stable presentations may have commercial potential in markets where cold-chain access, pharmacy compounding, or pediatric dosing creates product limitations. Local regulatory requirements and antimicrobial stewardship policies must be assessed before commercial launch.

How does Cipro compare with competing fluoroquinolones?

Product	Formulation opportunity	Competitive pressure	Key risk
Ciprofloxacin	Suspension, ophthalmic, otic, IV, modified release	Very high generic competition	Safety warnings and stewardship restrictions
Levofloxacin	Tablets, IV, ophthalmic	High	Broad generic availability
Moxifloxacin	Tablets, IV, ophthalmic	High	Strong competition and restricted use
Ofloxacin	Ophthalmic and otic products	High	Price-driven market
Delafloxacin	Newer oral and IV products	Lower generic pressure than Cipro	Higher cost and narrower positioning

Ciprofloxacin’s advantage is manufacturing familiarity and broad global availability. Its disadvantages include extensive generic competition, drug-interaction management, resistance concerns, and fluoroquinolone class safety warnings.

What generic launch risks exist for a new Cipro product?

The principal risks are:

1. Inability to demonstrate bioequivalence after taste masking or controlled release.
2. Ciprofloxacin binding to excipients or mineral components.
3. Poor suspension redispersibility and dose nonuniformity.
4. In-use microbial growth after reconstitution.
5. Ophthalmic irritation from preservatives or buffer systems.
6. Patent claims covering a narrow formulation architecture.
7. Price erosion from established generic suppliers.
8. Limited formulary uptake because ciprofloxacin is often reserved for targeted indications.
9. Manufacturing variability in high-dose tablets.
10. Supply disruption caused by API quality or facility concentration.

A product with the lowest manufacturing cost may still fail commercially if it has poor pharmacy handling characteristics or cannot secure hospital contracts.

How should a company build an excipient and IP strategy for Cipro?

A practical strategy is to select one product problem and support it with comparative data.

The preferred development sequence is:

1. Screen excipients for ciprofloxacin compatibility, dissolution impact, and mineral interaction.
2. Select a clinically meaningful target such as taste, reconstitution, ocular tolerability, or in-use stability.
3. Develop a formulation that uses common, globally accepted excipients where possible.
4. Generate head-to-head data against the reference product or leading generic.
5. File composition, process, and use claims before broad commercial disclosure.
6. Choose ANDA or 505(b)(2) based on the degree of formulation difference.
7. Protect know-how through process controls, particle engineering, coating conditions, and packaging design.
8. Prioritize markets where the formulation benefit supports a price premium.

The best commercial position is likely a differentiated ciprofloxacin suspension or sterile local-delivery product, not another immediate-release tablet.

Key Takeaways

• Cipro’s core ciprofloxacin patent protection is expired, and standard tablet products are highly commoditized.
• Excipient-driven opportunity is concentrated in taste masking, oral suspension performance, ophthalmic tolerability, preservative reduction, and sterile product stability.
• Ciprofloxacin’s interactions with polyvalent cations must be considered during excipient selection and labeling.
• A conventional generic product would usually follow the ANDA pathway; a materially different delivery system may require 505(b)(2).
• No biosimilar risk applies because ciprofloxacin is a small-molecule drug.
• Stronger formulation patents require measurable performance benefits and non-obvious excipient combinations.
• Commercial success depends on supply reliability, tender access, pharmacy usability, and regulatory execution as much as on formulation novelty.
• The most attractive near-term opportunity is a palatable, stable, syringeable pediatric suspension or a differentiated ophthalmic or otic product.

FAQs

Can ciprofloxacin be formulated with calcium or magnesium excipients?

Ciprofloxacin can interact with polyvalent cations, which may reduce absorption. Calcium, magnesium, aluminum, iron, and zinc-containing excipients require specific compatibility and labeling assessment.

Is a taste-masked ciprofloxacin suspension patentable?

It may be patentable if the formulation combines a non-obvious taste-masking architecture with demonstrated release, stability, dose uniformity, or sensory advantages. Routine use of common sweeteners or flavors is unlikely to provide broad protection.

Does ciprofloxacin require a biosimilar application?

No. Ciprofloxacin is a synthetic small molecule. US competitors generally use the ANDA pathway or, for materially different products, the 505(b)(2) pathway.

What is the best dosage form for ciprofloxacin product differentiation?

Oral suspension is the strongest general opportunity because bitterness, redispersion, dosing accuracy, and in-use stability create identifiable patient and pharmacy problems.

Can a preservative-free ciprofloxacin eye drop command a premium?

Potentially. The product would need a credible tolerability advantage, validated sterile container technology, reliable multidose microbial protection or unit-dose packaging, and evidence that purchasers will pay for the benefit.

References

1. U.S. Food and Drug Administration. (2023). Cipro (ciprofloxacin hydrochloride) prescribing information. Bayer HealthCare Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024). Approved drug product database and Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2018). Fluoroquinolone antimicrobial drugs: Drug safety communication. https://www.fda.gov/

6. U.S. Patent and Trademark Office. (1987). U.S. Patent No. 4,670,444: 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid.